ICH Q8, Q11 and Q12: from development knowledge to managed change
What you learn in development decides how freely you can change the process later. Q8, Q11 and Q12 connect the two.
In Short
- Moving within an approved design space is not a change.
- Justify your starting material under Q11.
- Established conditions are agreed with the regulator.
Q8(R2) covers pharmaceutical development, Q11 covers drug substance development, and Q12 covers lifecycle management after approval. FDA lists all three as final guidance. They shape what goes into a regulatory submission and how later changes are reported. This guide is for CMC, development and quality teams. Sources were checked on 2 Oct 2026.
How the three fit
Q8(R2) and Q11 explain how development knowledge supports a control strategy. Q12 then uses that knowledge to agree which elements are established conditions, so changes elsewhere can be managed in your quality system with less regulatory filing.
Which guideline answers which question
| Guideline | Question it answers |
|---|---|
| Q8(R2) | What development knowledge supports this drug product and its control strategy? |
| Q11 | How was the drug substance developed, and where does GMP manufacture start? |
| Q12 | Which elements are established conditions, and how will planned changes be handled? |
- Q8(R2)
- Question it answers
- What development knowledge supports this drug product and its control strategy?
- Q11
- Question it answers
- How was the drug substance developed, and where does GMP manufacture start?
- Q12
- Question it answers
- Which elements are established conditions, and how will planned changes be handled?
Design Space and Control Strategy
A design space is the combination of inputs and process parameters shown to assure quality. Moving within an approved design space is not treated as a change.
More on design Space and Control Strategy
The control strategy is the planned set of controls, from material attributes to in-process tests, that keeps the process on target.
Starting Materials under Q11
Q11 asks you to justify the proposed starting material, considering how far it sits from the final drug substance and how impurities are controlled. Agencies frequently question this choice.
Established Conditions and Change Protocols
Q12 introduces established conditions, the legally binding elements of the approval, and post-approval change management protocols that agree in advance how a planned change will be assessed. The regional reporting category still applies.
Is this change inside or outside what was approved?
Pick a proposed change.
- Record it in your quality system.
Where V5 fits
V5 keeps change control with impact assessment and approvals, master records, laboratory results and trends. Your regulatory team decides established conditions and reporting categories; regulators approve submissions.
More on where V5 fits
V5 does not prepare filings.
Questions
Are Q8, Q11 and Q12 law?
No. They are harmonised guidance that FDA lists as final. How they apply depends on your submission and the region's reporting rules.
Is a change inside the design space a regulatory change?
Movement within an approved design space is not considered a change under Q8(R2). Changes to the design space itself follow the regional change process.
What are established conditions?
Under Q12, they are the elements of an approval that are legally binding and need regulatory action to change, as agreed with the regulator.
Does V5 decide the reporting category for a change?
No. V5 records the change, assessment and approvals. Your regulatory team decides the reporting category.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
Keep reading
ICH E6(R3) Good Clinical Practice: What Changes for Sponsors and Suppliers
ICH Q10 Pharmaceutical Quality System Guide: Four Elements, Management Review
Supplement Stability Testing: Shelf-Life Dating Using ICH Q1 Principles
ICH Q7 Guide: GMP for Active Pharmaceutical Ingredients
ICH Q9(R1) Quality Risk Management Guide: Formality, Subjectivity, Decisions